ArticleJournal of clinical medicine2025

Long-Term Outcomes of Guselkumab and Risankizumab for the Management of Moderate-to-Severe Psoriasis in the Elderly: Results from a Real-World Retrospective Study.

Ioannis-Alexios Koumprentziotis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.